Zacks: Brokerages Expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) Will Announce Earnings of $0.63 Per Share
Equities analysts expect Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to post $0.63 earnings per share for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Teva Pharmaceutical Industries’ earnings, with the highest EPS estimate coming in at $0.67 and the lowest estimate coming in at $0.57. Teva Pharmaceutical Industries reported earnings of $0.53 per share during the same quarter last year, which suggests a positive year over year growth rate of 18.9%. The business is expected to report its next quarterly earnings report on Wednesday, February 12th.
On average, analysts expect that Teva Pharmaceutical Industries will report full-year earnings of $2.39 per share for the current year, with EPS estimates ranging from $2.25 to $2.45. For the next fiscal year, analysts forecast that the firm will post earnings of $2.51 per share, with EPS estimates ranging from $2.13 to $2.74. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.56 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). The business had revenue of $4.26 billion during the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%.
In related news, VP Hafrun Fridriksdottir sold 4,310 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.49, for a total transaction of $45,211.90. Following the sale, the vice president now owns 24,883 shares of the company’s stock, valued at approximately $261,022.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.49% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Pacer Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at about $32,000. AdvisorNet Financial Inc raised its holdings in shares of Teva Pharmaceutical Industries by 71.3% in the 3rd quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after acquiring an additional 1,525 shares in the last quarter. Motco purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $28,000. Lindbrook Capital LLC raised its holdings in shares of Teva Pharmaceutical Industries by 76.6% in the 3rd quarter. Lindbrook Capital LLC now owns 4,461 shares of the company’s stock valued at $31,000 after acquiring an additional 1,935 shares in the last quarter. Finally, G&S Capital LLC raised its holdings in shares of Teva Pharmaceutical Industries by 49.9% in the 3rd quarter. G&S Capital LLC now owns 6,012 shares of the company’s stock valued at $41,000 after acquiring an additional 2,000 shares in the last quarter. 53.38% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE:TEVA opened at $10.04 on Friday. The company has a market capitalization of $10.32 billion, a PE ratio of 3.59, a price-to-earnings-growth ratio of 0.90 and a beta of 1.81. The company has a debt-to-equity ratio of 1.62, a current ratio of 0.89 and a quick ratio of 0.56. The business has a fifty day moving average price of $9.76 and a two-hundred day moving average price of $8.40. Teva Pharmaceutical Industries has a 1 year low of $6.07 and a 1 year high of $20.21.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Featured Story: Trading Stocks – What are percentage gainers?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.